Healthcare, Pharma & Life Sciences

Potomac, Md. – November 03, 2026 -- Creatv MicroTech is applying for CLIA approval for its LifeTracDx blood test and plans to file for FDA approvals across multiple cancer diagnostic applications, according to a profile of founder Cha-Mei Tang issued by The Inner Circle.

Microfilter built in 2010 led to discovery of cancer-associated macrophage-like cells

Creatv developed a microfilter in 2010 to capture circulating tumor cells from the blood of cancer patients. From the first patient sample, the filter also captured numerous giant cells that cancer researchers had previously ignored. Tang and Daniel L. Adams, now Chief Scientific Officer, analyzed the cells and identified them as macrophages that engulf tumor cells. The team named them cancer associated macrophage-like cells (CAMLs).

Stockholm – November 03, 2026 -- Sobi (STO: SOBI) will present six abstracts on two late-stage gout assets, pozdeutinurad (AR882) and nanoencapsulated sirolimus plus pegadricase (NASP), at ACR Convergence 2026, the American College of Rheumatology annual meeting, in Orlando, Florida, on 6–11 November 2026.

Phase 3 REDUCE-2 results for pozdeutinurad headline the program

The presentations include results from the Phase 3 REDUCE-2 study of pozdeutinurad, an investigational once-daily oral, highly selective URAT1 inhibitor for uncontrolled gout. REDUCE-2 is one of two 12-month, randomised, double-blind, placebo-controlled Phase 3 studies, alongside REDUCE-1, that are evaluating the drug in more than 800 patients. Both trials assess its ability to lower serum urate (SU) in patients with uncontrolled gout.

Earlier Phase 2 studies showed a sustained SU reduction, dissolution of tophi and a generally well-tolerated safety profile, according to Sobi.

STOCKHOLM – November 03, 2026 -- The U.S. Patent and Trademark Office has granted Moberg Pharma a patent on an improved dosing regimen for MOB-015, its topical onychomycosis drug, with a projected expiry in December 2041. The U.S. is the first market to grant a patent on the new dosing.

Patent draws on European approval studies and North American Phase 3 data

The patent covers new dosing approaches for MOB-015. It rests on clinical results from the studies behind the European approval and from the company's most recently completed Phase 3 study in North America. Dosing patent applications in other markets remain under examination.

Milford, Mass. – November 03, 2026 -- Waters Corporation raised every component of its full-year 2026 guidance after third-quarter revenue of $1.767 billion beat the guidance midpoint by $14 million and adjusted EPS rose 21% to $4.10. The company lifted its total reported revenue outlook by $43 million at the midpoint.

Organic revenue climbs 9% as acquired businesses add $896 million

Organic revenue reached $871 million, up from $800 million a year earlier. That is 9% growth as reported and 10% in constant currency. The acquired Biosciences and Diagnostic Solutions businesses contributed $896 million, compared with $885 million on a prior-year comparable basis.

GAAP diluted EPS fell to $0.82 from $2.50 a year earlier. Waters attributed the drop to acquisition-related purchase accounting charges, acquisition-related costs and restructuring costs. Adjusted EPS rose from $3.40 to $4.10.

SOUTH SAN FRANCISCO – November 03, 2026 -- IDEAYA Biosciences (Nasdaq: IDYA) completed its first new drug application for darovasertib plus crizotinib in metastatic uveal melanoma during the third quarter, and ended the quarter with $1.15 billion in cash, cash equivalents and marketable securities as of September 30, 2026. Cash runway guidance into 2030 is unchanged.

Berlin – November 03, 2026 -- APOTHEKENTOUR closed its 2026 Germany season with a record 29,700 guests across twelve cities, and organizers are expanding to up to 50 partner companies for 2027.

The final stop in Karlsruhe's Gartenhalle drew more than 2,300 visitors. The event is powered by APOTHEKE ADHOC and PTA IN LOVE and brought together pharmacists, pharmacy technicians (PTA) and pharmacy clerks (PKA) with 45 partner companies.

Event engagement metrics show three-hour stays and 40% first-time visitors

Four Silent-Lab lounges hosted more than 1,900 talks over 24 event days. Average dwell time exceeded three hours per guest. Roughly 40% of attendees were first-time visitors.

Tom Bellartz, CEO of ELPATO Medien GmbH, said the 29,707 guests attend on their free weekends, stay for several hours and seek direct exchange with partner teams. He described the format as a space where pharmacy teams, brands and knowledge meet.

Duluth, Georgia – November 03, 2026 -- Bridge to Life Ltd. has secured a Health Canada Medical Device License for its VitaSmart HOPE System and an FDA Breakthrough Device Designation for investigational use in donor intestines, widening the commercial reach of its organ perfusion platform in North America.

Health Canada license opens liver transplant centers nationwide

The Canadian license covers hypothermic oxygenated perfusion (HOPE) of donor livers and makes VitaSmart available to transplant centers across Canada. More than 4,000 Canadians are on organ transplant waiting lists, and over 100,000 Americans are waiting in the U.S. Bridge to Life executives attended the Canadian Society of Transplantation Annual Scientific Meeting in Montreal in October as part of the market launch.

Burlington – November 03, 2026 -- PAQ Therapeutics will present the first clinical data for PT0253, its selective KRAS G12D degrader, in a late-breaking oral session at the 38th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics (ENA 2026) in Barcelona, Spain, on November 20.

Phase 1 data in advanced solid tumors will cover safety and antitumor activity

The presentation reports findings from the company's ongoing Phase 1 trial in patients with advanced solid tumors. The abstract title (6LBA) describes a differentiated safety profile and antitumor activity for PT0253, including in patients who received prior (K)RAS-targeted therapy.

The slot is scheduled for 12:36-12:44 p.m. CET in Plenary Session 6, "Proffered Papers: Advances in Targeting RAS." ENA 2026 runs November 18-20.

Bad Homburg – November 03, 2026 -- Fresenius Medical Care narrowed its 2026 operating income outlook to between flat and negative mid-single-digit growth after third-quarter reported operating income fell 19% to EUR 384 million. Reported net income dropped 42%, mainly because of EUR 108 million in one-time costs tied to the company's China strategy refinement.

The company's revenue outlook remains broadly flat. New CEO Shervin J. Korangy said the narrowed range reflects operating income in the first nine months and expected fourth-quarter headwinds, placing 2026 in the lower half of the previous range.

Berlin – November 03, 2026 -- The Scientific Institute of the AOK (WIdO) expects net drug costs in Germany's statutory health insurance (GKV) to rise 2.2% to 2.8% in 2027, a sharp slowdown from the 5.5% growth projected for 2026. The brake comes from the GKV Contribution Rate Stabilisation Act (GKV-BStabG), whose additional manufacturer discount is meant to relieve payers by almost EUR 2.5 billion. WIdO says the structural drivers of spending remain untouched.